The Pharmaceutical Journal
Vol 277 No 7419 p360
23 September 2006

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Pegaptanib in diabetic retinopathy

Patients with diabetic retinopathy treated with the selective vascular endothelial growth factor inhibitor pegaptanib have improved visual acuity compared with control patients (+4.7 letters versus –0.4 letters; P=0.04), and are less likely to need laser treatment (25 per cent versus 48 per cent; P=0.042).

So suggests a trial of 172 patients presented at the European VitreoRetinal Society meeting in Cannes last week.